EyePoint Pharmaceuticals Announces Sale of YUTIQ® to Alimera Sciences, Inc. for $82.5 Million Cash Plus Royalties
May 18, 2023 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
–$75M paid at closing with an additional $7.5M payable in equal quarterly installments in 2024 – All outstanding bank debt retired and expected cash runway extended into 2025 – EyePoint...
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 16, 2023 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., May 16, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve...
EyePoint Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Developments
May 03, 2023 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
– Completed enrollment in the oversubscribed Phase 2 DAVIO 2 clinical trial evaluating EYP-1901 in wet age-related macular degeneration (AMD); topline data anticipated in 4Q 2023 – Enrollment...
EyePoint Pharmaceuticals to Report First Quarter 2023 Financial Results on May 3, 2023
April 26, 2023 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of...
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 17, 2023 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., April 17, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of...
EyePoint Pharmaceuticals Completes Enrollment in Oversubscribed Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for Maintenance Treatment of Wet AMD
March 27, 2023 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
- Significant investigator and patient interest drove strong recruitment, exceeding enrollment goals - Topline DAVIO 2 data anticipated in Q4 2023 WATERTOWN, Mass., March 27, 2023 (GLOBE...
EyePoint Pharmaceuticals Announces Upcoming Data Presentations at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
March 20, 2023 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
- Positive neuroprotective effect of vorolanib, the active drug in EYP-1901, in a widely validated retinal detachment model demonstrates a potential new mechanism of action for the treatment of...
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Developments
March 02, 2023 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
– Phase 2 DAVIO 2 clinical trial in wet AMD on track with topline data anticipated by year-end 2023 – – Phase 2 PAVIA clinical trial in non-proliferative diabetic retinopathy (NPDR) on track with...
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
February 27, 2023 08:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients...
EyePoint and Rallybio Announce Research Collaboration to Evaluate Rallybio’s Inhibitor of Complement Component 5 (C5) and EyePoint’s Proprietary Durasert® Technology for Sustained Intraocular Delivery in Geographic Atrophy
February 27, 2023 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass. and NEW HAVEN, Conn., Feb. 27, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve...